慢性疼痛市場：薬剤クラス別、適応症別、用途別、流通チャネル別、地域別

世界の慢性疼痛市場は、2025年に773億米ドルと推定され、2032年には1,258億4,000万米ドルに達すると予測され、2025～2032年までの年間平均成長率（CAGR）は7.2％で成長すると予測されています。

図.慢性疼痛市場シェア（%）、2025年地域別

慢性痛とは、3ヵ月以上続く痛み、または通常の治癒期間を過ぎた痛みと定義されます。慢性疼痛を引き起こす疾患は数多く、関節炎、腰痛、がん、神経疾患、線維筋痛症など多岐にわたります。座りがちなライフスタイルや慢性疾患の増加は、世界的に慢性疼痛の有病率を高める可能性があります。慢性疼痛は、可動性や日常生活機能を制限することにより、生活の質に悪影響を及ぼします。世界の慢性疼痛市場は、疼痛管理用薬剤、神経調節装置、その他の治療手段で構成され、患者の苦痛を和らげ転帰を改善します。このような状態に陥りやすい高齢者の急増、医療支出の増加、新製品の発売、管理オプションに関する意識の高まりが市場成長の原動力となります。

市場力学

慢性疾患や傷害の有病率の増加は、世界の慢性疼痛の発生率上昇に大きく寄与しています。これには変形性関節症や腰痛などの筋骨格系疾患が含まれます。このような疾患に罹患しやすい高齢者の増加は、市場成長の原動力となります。さらに、医療支出の増加、新製品のイノベーション、高額な治療オプションに対する決済能力も市場成長の原動力となります。しかし、ジェネリック医薬品のような代替品の存在、服薬コンプライアンス違反、特定の治療法の副作用などは、市場参入企業に課題をもたらす可能性があります。さらに、新製品承認のための規制上のハードルも市場成長の妨げとなる可能性があります。新興国は産業参入企業に大きなビジネス機会を記載しています。疼痛治療法の技術的進歩は、市場成長に新たな道を開く可能性があります。

本調査の主要特徴

本レポートでは、世界の慢性疼痛市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模（10億米ドル）と複合年間成長率（CAGR%）を掲載しています。

また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。

また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域による展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。

世界の慢性疼痛市場における主要企業を、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいてプロファイルしています。

本調査の対象となる主要企業には、Pfizer、Eli Lilly、GlaxoSmithKline、Novartis、Johnson & Johnson,、AstraZeneca、Purdue Pharma、Endo Pharmaceuticals、Teva Pharmaceuticals Industries Ltd.、Mallinckrodt Pharmaceuticalsが含まれます。

本レポートから洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。

世界の慢性疼痛市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この産業の様々な利害関係者に対応しています。

利害関係者は、世界の慢性疼痛市場分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー

第3章 市場力学、規制、動向分析

• 市場力学
• 影響分析
• 規制シナリオ
• 製品の発売/承認
• PEST分析
• ポーター分析
• 合併と買収のシナリオ

第4章 世界の慢性疼痛市場、薬剤クラス別、2020～2032年（10億米ドル）

• イントロダクション
• オピオイド
• 非ステロイド性抗炎症薬（NSAID）
• 抗けいれん薬
• 抗うつ薬
• その他

第5章 世界の慢性疼痛市場、適応症別、2020～2032年（10億米ドル）

• イントロダクション
• 神経障害性疼痛
• 関節炎の痛み
• 慢性的な腰痛
• がんの痛み
• 片頭痛
• 線維筋痛症
• その他

第6章 世界の慢性疼痛市場、用途別、2020～2032年（10億米ドル）

• イントロダクション
• 筋骨格
• 神経障害
• 腫瘍学
• その他

第7章 世界の慢性疼痛市場、流通チャネル別、2020～2032年（10億米ドル）

• イントロダクション
• 病院薬局
• 小売薬局
• オンライン薬局

第8章 世界の慢性疼痛市場、地域別、2020～2032年（10億米ドル）

• イントロダクション
• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第9章 競合情勢

• Pfizer Inc.
• Johnson & Johnson
• GlaxoSmithKline PLC
• Bayer AG
• Novartis AG
• Endo Pharmaceuticals
• Bristol-Myers Squibb
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Reckitt Benckiser Group plc
• Medtronic plc
• AstraZeneca PLC
• Becton, Dickinson and Company
• AbbVie Inc.
• Horizon Therapeutics
• Mallinckrodt Pharmaceuticals
• Zynerba Pharmaceuticals
• Neurocrine Biosciences
• Sorrento Therapeutics
• Cypress Pharmaceutical

第10章 アナリストの推奨事項

• 隆盛と衰退
• 一貫型機会マップ

第11章 参考文献と調査手法

• 参考文献
• 調査手法
• 出版社について

Global Chronic Pain Market is estimated to be valued at USD 77.30 Bn in 2025 and is expected to reach USD 125.84 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2032.

Figure. Chronic Pain Market Share (%), By Region 2025

Chronic pain is defined as any pain lasting for more than three months or past the normal time of healing. The conditions that cause chronic pain are numerous and wide-ranging from arthritis, back pain, cancer, neurological disorders and fibromyalgia among others. Sedentary lifestyles and rising chronic diseases can increase the prevalence of chronic pain globally. It negatively impacts quality of life by limiting mobility and daily functioning. Global chronic pain market consists of drugs for pain management, neuromodulation devices, and other treatment modalities that provide relief and improve patient outcomes. Rapid growth in geriatric population who are more prone to such conditions, rise in healthcare expenditure, new product launches, and increasing awareness about management options can drive the market growth.

Market Dynamics:

Increasing prevalence of chronic diseases and injuries has significantly contributed to rising incidence of chronic pain worldwide. These include musculoskeletal disorders like osteoarthritis and lower back pain. Growing geriatric population who are more susceptible to such conditions can drive the market growth. Furthermore, greater healthcare spending, new product innovations, and ability to pay for expensive treatment options can also drive the market growth. However, presence of alternatives like generic drugs, non-compliance to medications, and side effects of certain therapies can pose challenges to market players. Moreover, regulatory hurdles for new product approvals can also hamper the market growth. Emerging economies provide major opportunities for industry players. Technological advancements in pain treatment modalities can open new avenues for the market growth.

Key features of the study:

This report provides in-depth analysis of the global chronic pain market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global chronic pain market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer, Eli Lilly, GlaxoSmithKline, Novartis, Johnson & Johnson, AstraZeneca, Purdue Pharma, Endo Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., and Mallinckrodt Pharmaceuticals

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global chronic pain market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic pain market

Detailed Segmentation-

• By Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
  • Opioids
  • Non-steroidal anti-inflammatory drugs (NSAIDS)
  • Anticonvulsants
  • Antidepressants
  • Others
• By Indication Insights (Revenue, USD Bn, 2020 - 2032)
  • Neuropathic pain
  • Arthritis pain
  • Chronic back pain
  • Cancer pain
  • Migraine
  • Fibromyalgia
  • Others
• By Application Insights (Revenue, USD Bn, 2020 - 2032)
  • Musculoskeletal
  • Neuropathy
  • Oncology
  • Others
• By Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Pfizer Inc.
  • Johnson & Johnson
  • GlaxoSmithKline PLC
  • Bayer AG
  • Novartis AG
  • Endo Pharmaceuticals
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries Ltd.
  • Reckitt Benckiser Group plc
  • Medtronic plc
  • AstraZeneca PLC
  • Becton, Dickinson and Company
  • AbbVie Inc.
  • Horizon Therapeutics
  • Mallinckrodt Pharmaceuticals
  • Zynerba Pharmaceuticals
  • Neurocrine Biosciences
  • Sorrento Therapeutics
  • Cypress Pharmaceutical

Table of Contents

1. RESEARCH OBJECTIVES AND ASSUMPTIONS

• Research Objectives
• Assumptions
• Abbreviations

2. MARKET PURVIEW

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Chronic Pain Market, By Drug Class
  • Global Chronic Pain Market, By Indication
  • Global Chronic Pain Market, By Application
  • Global Chronic Pain Market, By Distribution Channel
  • Global Chronic Pain Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Chronic Pain Market, By Drug Class, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Opioids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Non-steroidal anti-inflammatory drugs (NSAIDS)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Anticonvulsants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Antidepressants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Chronic Pain Market, By Indication, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Neuropathic pain
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Arthritis pain
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Chronic back pain
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Cancer pain
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Migraine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Fibromyalgia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Chronic Pain Market, By Application, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Musculoskeletal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Neuropathy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Chronic Pain Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Chronic Pain Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Endo Pharmaceuticals
• Bristol-Myers Squibb
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Reckitt Benckiser Group plc
• Medtronic plc
• AstraZeneca PLC
• Becton, Dickinson and Company
• AbbVie Inc.
• Horizon Therapeutics
• Mallinckrodt Pharmaceuticals
• Zynerba Pharmaceuticals
• Neurocrine Biosciences
• Sorrento Therapeutics
• Cypress Pharmaceutical

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us